Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (45)

2024

  1. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

2022

  1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  2. Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients

    Pharmaceutics, Vol. 14, Núm. 4

  3. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2020

  1. Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy

    European Journal of Pharmaceutical Sciences, Vol. 153

2019

  1. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

2017

  1. P567Early diagnosis of anthracycline induced cardiotoxicity in a swine model by serial multiparametric cardiac magnetic resonance

    European Heart Journal, Vol. 38, Núm. suppl_1

2016

  1. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma

    British Journal of Clinical Pharmacology, Vol. 82, Núm. 6, pp. 1517-1527

2014

  1. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

  2. Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 955-956, Núm. 1, pp. 93-97

2013

  1. Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43

2011

  1. Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  2. Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  3. Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients

    Therapeutic Drug Monitoring, Vol. 33, Núm. 5, pp. 573-582

2010

  1. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

    Breast Cancer Research and Treatment, Vol. 123, Núm. 1, pp. 149-157

  2. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy

    Therapeutic Drug Monitoring, Vol. 32, Núm. 5, pp. 579-585

2009

  1. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798

  2. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280